LyGenesis Report issue

For profit Phase 1 Phase 2
Founded: Pittsburgh PA United States (2017)

Organization Overview

First Clinical Trial
2021
NCT04496479
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

LyGenesis, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

allogenic hepatocytes (1 trial)

Drugs in Phase 1 Trials (1)

Key: LyGenesis (0) Acquired (1)

rotigotine (neupro) (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2